Loading...
In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively. © 2015 by The American Society of Hematology.
Type
research article
PubMed ID
25721043
Authors
Publication date
2015
Published in
Volume
125
Issue
9
Start page
1362
End page
3
Peer reviewed
REVIEWED
EPFL units
Available on Infoscience
March 9, 2015
Use this identifier to reference this record